An evaluation of infants with persistent regurgitation who were referred to a pediatric gastroenterology service showed that most infants who were prescribed antireflux drugs before referral did not meet diagnostic criteria for gastroesophageal reflux disease (GERD). Of 64 infants who had been evaluated for symptoms of regurgitation lasting more than two weeks, more than 90% had been given antireflux medication.
Thickening of feeds also was a common intervention before referral. Yet diagnostic tests indicated that only eight of the 64 infants had GERD, based on abnormal esophageal pH with or without impedance studies.
Investigators performed extended esophageal pH/impedance monitoring studies on 44 of the infants, 42 of whom already were on antireflux medications. Only eight of these 44 (18%) had abnormal studies. Of the remaining 20 infants who did not get a pH/impedance study, four had pyloric stenosis and one had renal tubular acidosis. The remaining 15 infants were thriving and had only regurgitation without accompanying symptoms.
Commentary:
The authors suggest that regurgitation in the absence of significant reflux disease should be managed conservatively, without medications. They consider raising the stakes only in the face of poor weight gain, persistent crying and irritability, feeding problems, recurrent respiratory symptoms, hoarseness, hematemesis, or persistently disturbed sleep. Using these criteria, most spitting infants could be kept off antireflux medications, saving money and avoiding potential medication side effects. This seems like good advice to me.
Hematocrit levels in newborns: EPP vs DCC study reveals surprising findings
November 15th 2023A recent study in JAMA Network Open investigates the impact of extrauterine placental perfusion versus delayed cord clamping on hematocrit levels in newborns, shedding light on potential alternatives for optimizing infant outcomes during birth.
RSV: 1 year post-tripledemic emergency department update
October 22nd 2023Steven Selbst, MD, provides a quick update on what he has noticed in his hospital when it comes to RSV-associated emergency department visits and how they compare to this time last year, during the "tripledemic." This interview was conducted at the 2023 American Academy of Pediatrics National Conference and Exhibition in Washington DC.
Navigating a complex case of pediatric COVID-19 with immunomodulatory therapies
October 21st 2023Eculizumab and anakinra should be considered in critically ill patients with severe infections that require immunomodulating therapies for life-threatening dysregulation, according to a poster session at the 2023 American Academy of Pediatrics National Conference & Exhibition.